- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01158352
Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children (Formula)
Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children
Study design:
Double blind, randomized, placebo controlled study.The proposed study will consist of two main segments:
- Segment 1 is aimed to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean prepubertal children on weight SDS, height SDS, BMI SDS and growth velocity
- Segment 2 is aimed to explore the eating behavior of idiopathic short stature and lean prepubertal children against their sibling who have a normal height and body weight and to find out whether there is a difference in eating patterns and quality of life between idiopathic short stature and lean prepubertal children and children with normal height and body weight
Segment 1
Population:
200 subjects and controls will be recruited to segment 1 of the proposed study, 100 at each group.
Participants will be recruited from healthy children who will be referred to either the institute for endocrinology or the gastroenterology unit, at Schneider Children's Medical Center for growth assessment, due to low height and weight, in whom, no gastrointestinal morbidity or other underlying cause was found.
Methods:
Randomization & Blinding:
Participants will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the first 6 months of the study.
Treatment:
Participants in the intervention group will be treated with a nutritional supplementation standardized formula.Participants in the control group will be instructed to consume the same volume of formula as was calculated if they were in the intervention group.
Treatment duration:
The study will be divided into two treatment periods: 6 months of intervention versus active placebo followed with additional 6 months (an extension period), in which participants at the intervention group will be offered to extend the intervention period and participants at the control arm will be offered to switch to the intervention group.
Study Schedule:
Follow up visits will take place at 0, 3, 6, 9 and 12 months and will include:
Demographic data, medical history and growth data (month 0):
Demographic parameters, including birth date, gender, birth weight and length for gestational age, medical history and growth data, including height velocity, parent's and sibling's weight and height will be documented from patient's file.
- Nutritional assessment
Anthropometric assessment (months 0, 3, 6, 9 12):
- Height without shoes
- Length
- Weight with light cloths and without shoes
- MAC
- Body mass index (BMI) will be calculated from children's weight and height and age and gender specific BMI SDS will be calculated
- Body composition assessment using the method of bioelectrical impedance
- Laboratory parameters (months 0, 6 and 12):
- Sleeping Questionaire
Segment 2:
86 subjects and controls will be recruited to segment 2 of the proposed study
Population:
Short and lean prepubertal children participating at segment 1 of the study and who are at study entry under 10th percentile in height, when the weight percentile is equal or smaller to the height percentile. Only participants from segment 1 who have siblings with normal height and body weight for age and gender, will be able to participate in segment 2 of the study
Control group 1:
Sibling of participants in segment 1 of the study, who have a normal height- above 25th percentile and normal BMI for age and gender- above 5th percentile and under 85th percentile.
Control group 2:
Healthy children from the community who have a normal height above 25th percentile and normal BMI for age and gender above 5th percentile and under 85th percentile
Segment 2 of the study will be designed as a case- control study and will focus on the eating patterns, sleeping patterns and quality of life of participants at segment 1 at time 0 month of the study, before the beginning of the nutrition intervention. These findings will be compared to data of a control group, which will be comprised of siblings of participants in segment 1, with normal height and body weight which are matched in age.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Petaach-Tikva, Israel, 49202
- Schneider Children's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for participants at the intervention group (segments 1&2):
- Girls aged 3-7 years old and boys aged 3-8 years old
- Prepubertal - tanner stage 1
- Height, weight and BMI < 10th percentile for age and gender
- Availability of growth velocity data for at least 4 months prior to study entry.
- Signing inform consent forms
Exclusion Criteria for participants at the intervention group (segments 1):
- Diagnosis of GH Deficiency or treatment with GH
- Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems
- Any known gastrointestinal problem including absorption problems
- Any known organic reason for slow growth
- Any chronic treatment with medication that might effects appetite (for example SSRI's), weight or Growth.
Inclusion Criteria for participants at the control group (segments 2):
- Girls aged 3-8 years old and boys aged 3-9 years old
- Prepubertal - tanner stage 1
- Height ≥ 25th percentile for age and gender
- Proper proportion between weight and height- 5th ≤ BMI ≤ 85th
- Signing inform consent forms
Exclusion Criteria for participants at the control group (segments 2):
- Diagnosis of GH Deficiency or treatment with GH
- Any known chronic disease or dysmorphic syndrome including: bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardial, renal or pulmonary problems
- Any known gastrointestinal problem including absorption problems
- Any known organic reason for slow growth
- Any chronic treatment with medication that might effects appetite (for example SSRI's), weight or Growth
- Children with growth faltering during the previous year
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nutritional supplemntation formula
Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
|
Nutritional supplementation formula
|
Placebo Comparator: Placebo Comparator
Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
|
Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Height SDS (standard deviation score)
Time Frame: At 12 months
|
standard deviation score of patient's height at 12 months
|
At 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight SDS (standard deviation score)
Time Frame: At 12 months
|
Standard deviation score of patient's weight at 12 months
|
At 12 months
|
Weight/Height SDS (standard deviation score)
Time Frame: At 12 months
|
Standard deviation score of patient's Weight / Height ratio at 12 months
|
At 12 months
|
BMI SDS (standard deviation score)
Time Frame: At 12 months
|
standard deviation score of patient's BMI at 12 months
|
At 12 months
|
Growth Velocity
Time Frame: At 12 months
|
At 12 months
|
|
5.Sleeping Questionaire
Time Frame: At 12 months
|
At 12 months
|
|
Child Eating Behaviour Questionaire (CEBQ)
Time Frame: At 12 months
|
At 12 months
|
|
3-day food diary
Time Frame: At 12 months
|
At 12 months
|
|
Physical activity questionnaire
Time Frame: At study entry
|
At study entry
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Moshe Phillip, Prof, Schenider Children's Medical
Publications and helpful links
General Publications
- Yackobovitch-Gavan M, Lebenthal Y, Lazar L, Shalitin S, Demol S, Tenenbaum A, Shamir R, Phillip M. Effect of Nutritional Supplementation on Growth in Short and Lean Prepubertal Children after 1 Year of Intervention. J Pediatr. 2016 Dec;179:154-159.e1. doi: 10.1016/j.jpeds.2016.08.100. Epub 2016 Sep 30.
- Lebenthal Y, Yackobovitch-Gavan M, Lazar L, Shalitin S, Tenenbaum A, Shamir R, Phillip M. Effect of a nutritional supplement on growth in short and lean prepubertal children: a prospective, randomized, double-blind, placebo-controlled study. J Pediatr. 2014 Dec;165(6):1190-1193.e1. doi: 10.1016/j.jpeds.2014.08.011. Epub 2014 Sep 17.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- rmc005547ctil
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth
-
University of California, DavisCompletedGrowth Acceleration | Growth RetardationUnited States
-
Northwell HealthRecruitingGrowth | Growth Disorders | Growth Failure | Growth Hormone TreatmentUnited States
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in ChildrenIsrael, Denmark, Belgium, Spain, Macedonia, The Former Yugoslav Republic of, Turkey, United Kingdom, France, Slovenia, Czech Republic
-
Novo Nordisk A/SWithdrawnGrowth Hormone Disorder | Growth Hormone Deficiency in Children
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyFrance
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone Disorder | Adult Growth Hormone DeficiencyUnited States
-
University of CopenhagenUniversity of Aarhus; Arla FoodsCompletedGrowth Acceleration | Growth; Stunting, NutritionalDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
Clinical Trials on Nutritional supplementation formula
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnClinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Esophageal Adenocarcinoma... and other conditionsUnited States
-
Rabin Medical CenterRecruiting
-
Rabin Medical CenterRecruitingGrowth Retardation | IGHD - Isolated Growth Hormone DeficiencyIsrael
-
Rabin Medical CenterRecruitingLow Weight | Growth ProblemIsrael
-
Rabin Medical CenterCompletedLow Weight | Short Stature | Growth ProblemIsrael
-
Rabin Medical CenterNG Solutions LtdRecruitingADHD - Attention Deficit Disorder With HyperactivityIsrael
-
Uppsala UniversityVästmanland County Council, SwedenCompleted
-
Seoul St. Mary's HospitalCompletedProtein-Energy MalnutritionKorea, Republic of
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedEsophagitis | Mucositis | Malignant NeoplasmUnited States
-
Burke Rehabilitation HospitalCompleted